ARYA Atherosclerosis Journal

The use and the cost of inpatient diagnostic and therapeutic procedures for cardiovascular diseases in public hospitals of Isfahan, Iran

Document Type : Original Article

Authors

Reza Rezayatmand 1
Davood Nasiri 2
Alireza Khosravi Farsani 3
Farzaneh Mohammadi-Sefiddashti 1

1 Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Health Services Management, School of Management and Medical Information Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

3 Hypertension Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/arya.2025.45299.3061
Abstract
BACKGROUND: Cardiovascular diseases (CVDs) are the most important cause of mortality and disability worldwide, causing substantial personal, social, and economic problems. This study determined the use and Cost of inpatient diagnostic and therapeutic CVD procedures in Isfahan from 2019 to 2021.
METHODS: This descriptive study covered a three-year period (2019–2021). Data were gathered from the Health Information System of two public hospitals that carried out these procedures (Chamran and Khorshid hospitals) in Isfahan, Iran. A list of procedures was carefully chosen according to experts’ opinions, for which the use and cost of these procedures were extracted.
RESULTS: Coronary angiography demonstrated the highest annual average use (47.65%), while mitral valve repair showed the lowest (0.06%). The highest annual average total cost was seen in angioplasty (617,425,750,917 IRR), while the lowest was seen in mitral valve repair (2,375,305,232 IRR). Regarding cost per procedure, VSD surgery (409,107,479 IRR) had the highest annual average cost, while the lowest was seen in coronary angiography (56,340,938 IRR). A consistent upward trend in cost per procedure (in IRR) was observed across all procedures during the study period.
CONCLUSION: The majority of cardiovascular procedure costs are attributable to diagnosing and treating ischemic heart disease (IHD). Consequently, the increasing prevalence of CVDs particularly IHD coupled with the use of advanced technologies, imposes a significant financial burden on the healthcare system. This underscores the critical need for policy actions focused on lifestyle modification and primary prevention. Such measures are essential to curb rising costs and ensure healthcare system sustainability.

Keywords

Cardiovascular Diseases
Cost, Inpatients
Utilization Study
Angioplasty
Coronary Angiography
1. Gaidai O, Cao Y, Loginov S. Global Cardiovascular Diseases Death Rate Prediction. Curr Probl Cardiol. 2023 May;48(5):101622. https://doi.org/10.1016/j.cpcardiol.2023.101622
2. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. https://doi.org/10.1016/j.jacc.2020.11.010
3. Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. J Am Coll Cardiol. 2019 Nov 19;74(20):2529-32. https://doi.org/10.1016/j.jacc.2019.10.009
4. Sarrafzadegan N, Mohammmadifard N. Cardiovascular Disease in Iran in the Last 40 Years: Prevalence, Mortality, Morbidity, Challenges and Strategies for Cardiovascular Prevention. Arch Iran Med. 2019 Apr 1;22(4):204-10.
5. World Health Organization. Noncommunicable diseases: Progress monitor 2020. World Health Organization; 2020. Available from: https://www.who.int/publications/i/item/9789240000490
6. World Health Organization. Noncommunicable diseases country profiles 2018. Available from: https://www.who.int/publications/i/item/9789241514620
7. Givi M, Sarrafzadegan N, Garakyaraghi M, Yadegarfar G, Sadeghi M, Khosravi A, et al. Persian Registry Of cardioVascular diseasE (PROVE): Design and methodology. ARYA Atheroscler. 2017 Sep;13(5):236-44.
8. Mela A, Rdzanek E, Poniatowski ŁA, Jaroszyński J, Furtak-Niczyporuk M, Gałązka-Sobotka M, et al. Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015-2017 Years. Front Pharmacol. 2020 Sep 8;11:1231. https://doi.org/10.3389/fphar.2020.01231
9. Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health. 2018 Aug 6;18(1):975. https://doi.org/10.1186/s12889-018-5806-x
10. Rittiphairoj T, Bulstra C, Ruampatana C, Stavridou M, Grewal S, Reddy CL, et al. The economic burden of ischaemic heart diseases on health systems: a systematic review. BMJ Glob Health. 2025 Feb 12;10(2):e015043. https://doi.org/10.1136/bmjgh-2024-015043
11. Romiti S, Vinciguerra M, Saade W, Anso Cortajarena I, Greco E. Artificial Intelligence (AI) and Cardiovascular Diseases: An Unexpected Alliance. Cardiol Res Pract. 2020 Jun 27;2020:4972346. https://doi.org/10.1155/2020/4972346
12. Ma LY, Chen WW, Gao RL, Liu LS, Zhu ML, Wang YJ, et al. China cardiovascular diseases report 2018: an updated summary. J Geriatr Cardiol. 2020 Jan;17(1):1-8. https://doi.org/10.11909/j.issn.1671-5411.2020.01.001
13. Siqueira ASE, Siqueira-Filho AG, Land MGP. Analysis of the Economic Impact of Cardiovascular Diseases in the Last Five Years in Brazil. Arq Bras Cardiol. 2017 Jul;109(1):39-46. https://doi.org/10.5935/abc.20170068
14. Toth PP, Danese M, Villa G, Qian Y, Beaubrun A, Lira A, Jansen JP. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ. 2017 Jun;20(6):555-64. https://doi.org/10.1080/13696998.2017.1284078
15. Tarride JE, Lim M, DesMeules M, Luo W, Burke N, O’Reilly D, Bowen J, Goeree R. A review of the cost of cardiovascular disease. Can J Cardiol. 2009 Jun;25(6):e195-202. https://doi.org/10.1016/s0828-282x(09)70098-4
16. Emamgholipour S, Moeini S. Comparison of the economic burden between coronary artery bypass grafting and percutaneous coronary intervention at a one-year follow-up. Iran Heart J. 2022;23(1):106-11.
17. Osnabrugge RL, Speir AM, Head SJ, Jones PG, Ailawadi G, Fonner CE, et al. Prediction of costs and length of stay in coronary artery bypass grafting. Ann Thorac Surg. 2014 Oct;98(4):1286-93. https://doi.org/10.1016/j.athoracsur.2014.05.073
18. Zimmerman ME, Batlle JC, Biga C, Blankstein R, Ghoshhajra BB, Rabbat MG, et al. The direct costs of coronary CT angiography relative to contrast-enhanced thoracic CT: Time-driven activity-based costing. J Cardiovasc Comput Tomogr. 2021 Nov-Dec;15(6):477-83. https://doi.org/10.1016/j.jcct.2021.06.002
19. Ferreira C, Santana C, Paloni E, Bonachela F, Salles G, Brunet V, et al. Cost of angioplasty in Brazilian private hospitals. Value Health. 2013;16(3):A282-3.
20. Piot O, Defaye P, Lortet-Tieulent J, Deharo J-C, Beisel J, Vainchtock A, et al. Healthcare costs in implantable cardioverter-defibrillator recipients: A real-life cohort study on 19,408 patients from the French national healthcare database. Int J Cardiol. 2022 Feb 1;348:39-44. https://doi.org/10.1016/j.ijcard.2021.11.056
21. Tam DY, Sadri H. Annual Budget Impact Analysis Comparing Self-Expanding Transcatheter and Surgical Aortic Valve Replacement in Low-Risk Aortic Stenosis Patients. Can J Cardiol. 2022 Oct;38(10):1478-84. https://doi.org/10.1016/j.cjca.2022.06.005
22. Ferket BS, Ailawadi G, Gelijns AC, Acker MA, Hohmann SF, Chang HL, et al. Cost-Effectiveness of Mitral Valve Repair Versus Replacement for Severe Ischemic Mitral Regurgitation: A Randomized Clinical Trial From the Cardiothoracic Surgical Trials Network. Circ Cardiovasc Qual Outcomes. 2018 Nov 14;11(11):e004466. https://doi.org/10.1161/circoutcomes.117.004466
23. Ohri SK, Benedetto U, Luthra S, Grant SW, Goodwin AT, Trivedi U, et al. Coronary artery bypass surgery in the UK, trends in activity and outcomes from a 15-year complete national series. Eur J Cardiothorac Surg. 2022 Jan 24;61(2):449-56. https://doi.org/10.1093/ejcts/ezab391
24. Kolte D, Khera S, Dabhadkar KC, Agarwal S, Aronow WS, Timmermans R, et al. Trends in Coronary Angiography, Revascularization, and Outcomes of Cardiogenic Shock Complicating Non-ST-Elevation Myocardial Infarction. Am J Cardiol. 2016 Jan 1;117(1):1-9. https://doi.org/10.1016/j.amjcard.2015.10.006
25. Westaway S, Nye E, Gallagher C, Tu SJ, Clarke N, Hanna‐Rivero N, et al. Trends in the use, complications, and costs of permanent pacemakers in Australia: A nationwide study from 2008 to 2017. Pacing Clin Electrophysiol. 2021 Feb;44(2):266-73. https://doi.org/10.1111/pace.14161
26. Hassan A, Newman A, Ko DT, Rinfret S, Hirsch G, Ghali WA, et al. Increasing rates of angioplasty versus bypass surgery in Canada, 1994-2005. Am Heart J. 2010 Nov;160(5):958-65. https://doi.org/10.1016/j.ahj.2010.06.052
27. Roh SY, Choi JI, Kim MS, Cho EY, Kim YG, Lee KN, et al. Trends in the use of implantable cardioverter-defibrillators for prevention of sudden cardiac arrest: A South Korean nationwide population-based study. Pacing Clin Electrophysiol. 2019 Aug;42(8):1086-94. https://doi.org/10.1111/pace.13741
28. Saad AM, Kassis N, Isogai T, Gad MM, Ahuja KR, Abdelfattah O, et al. Trends in Outcomes of Transcatheter and Surgical Aortic Valve Replacement in the United States (2012-2017). Am J Cardiol. 2021 Feb 15;141:79-85. https://doi.org/10.1016/j.amjcard.2020.10.065
29. Zhou S, Egorova N, Moskowitz G, Giustino G, Ailawadi G, Acker MA, et al. Trends in MitraClip, mitral valve repair, and mitral valve replacement from 2000 to 2016. J Thorac Cardiovasc Surg. 2021 Aug;162(2):551-562.e4. https://doi.org/10.1016/j.jtcvs.2019.12.097
30. Park J, Yoon SJ, Han J, Song IG, Lim J, Shin JE, et al. Patent ductus arteriosus treatment trends and associated morbidities in neonates. Sci Rep. 2021 May 21;11(1):10689. https://doi.org/10.1038/s41598-021-89868-z
31. Dong Y, Zhang Y, Tong S, Jiang Z, Xu Z, Li X, et al. Analysis of the Seasonal Trend of Congenital Heart Defects. J Pediatr. 2019 Apr;207:29-33.e1. https://doi.org/10.1016/j.jpeds.2018.12.024
32. PPP conversion factor, private consumption (LCU per international $) - Iran, Islamic Rep. Available from: https://data.worldbank.org/indicator/PA.NUS.PRVT.PP?locations=IR
33. Moynihan R, Sanders S, Michaleff ZA, Scott AM, Clark J, To EJ, et al. Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open. 2021 Mar 16;11(3):e045343. https://doi.org/10.1136/bmjopen-2020-045343
34. Iran Health Insurance Organization, Inpatient Documents Statistics System. https://ihio.gov.ir/
35. Budget law of the Islamic Republic of Iran for the fiscal year 1400 (2021), Approved by the Islamic Consultative Assembly. Plan and Budget Organization, Tehran, Iran.
ARYA Atherosclerosis Journal
Volume 22, Issue 1
January and February 2026
Pages 18-26

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us